In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The global economic crisis triggered by the COVID-19 pandemic will undoubtedly put pressure on public spending and health care budgets.
The situation for many brings to mind the 2008 debt crisis and the slew of resulting European government austerity measures...